Unfortunately, it should be noted that an obvious limitation of both apatinib monotherapy and nivolumab monotherapy (PD-1 inhibitors) for patients with advanced GC was the relatively low ORR (<12%), which suggested that the combined administration of apatinib plus PD-1 blockades was of potent importance in this disease. The gene discussed is PDCD1; the disease is gastric cancer.